Abstract

Plecanatide, a guanylate cyclase-C agonist, has emerged as a promising therapeutic option for gastrointestinal disorders, specifically irritable bowel syndrome with constipation and chronic idiopathic constipation. This review provides a concise analysis of plecanatide drug, covering their mechanisms of action, clinical efficacy, safety profile, and implications for patient care. The bulk drug form and tablet presentation both offer unique advantages in the treatment landscape. As research continues, plecanatide stands out for its targeted approach and favorable safety profile, presenting a valuable option for a diverse range of patients.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call